Ignite Creation Date:
2024-05-06 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06229366
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2024-01-03
Brief Title:
Ac-225-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
Sponsor:
POINT Biopharma a wholly owned subsidiary of Eli Lilly and Company
Organization:
POINT Biopharma a wholly owned subsidiary of Eli Lilly and Company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Biochemically Recurrent Prostate Carcinoma |
| Prostate Cancer |
| Metastatic Castration-resistant Prostate Cancer |
Keywords:
| Name | View |
|---|---|
| mCRPC | View |
| BCR | View |
| Prostatic Neoplasms | View |
| Genital Neoplasms Male | View |
| Castration Resistant Prostate Cancer | View |
| Biochemically Recurrent Prostate Cancer | View |
| Oligometastatic Prostate Cancer | View |
| 225Ac-PSMA-62 | View |
| Ac-225-PSMA-62 | View |
| Actinium | View |
| Radioligand Therapy | View |
| Radiopharmaceuticals | View |
| Urogenital Neoplasm | View |